Efficacy and safety of ustekinumab treatment in elderly patients with psoriasis

Journal of Dermatology

Volumn 41, Issue 11, 2014, Pages 974-980

  Hayashi, Mitsuha ^a   Umezawa, Yoshinori ^a   Fukuchi, Osamu ^a   Ito, Toshihiro ^a   Saeki, Hidehisa ^a   Nakagawa, Hidemi ^a  

^a JIKEI UNIVERSITY SCHOOL OF MEDICINE   (Japan)

Author keywords

Biologics; Elderly patients; Psoriasis; Safety; Ustekinumab

Indexed keywords

ADALIMUMAB; C REACTIVE PROTEIN; CYCLOSPORIN; ETRETINATE; INFLIXIMAB; ISONIAZID; METHOTREXATE; URSODEOXYCHOLIC ACID; USTEKINUMAB; DERMATOLOGICAL AGENT;

ABNORMAL LABORATORY RESULT; AGED; ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; DERMATOLOGY LIVE QUALITY INDEX; DRUG DOSE INCREASE; DRUG EFFICACY; DRUG SAFETY; DRUG WITHDRAWAL; FEMALE; HUMAN; LATENT TUBERCULOSIS; LIVER TOXICITY; MALE; NAMED INVENTORIES, QUESTIONNAIRES AND RATING SCALES; OUTCOME ASSESSMENT; PHOTOTHERAPY; PROPHYLAXIS; PSORIASIS AREA AND SEVERITY INDEX; PSORIASIS VULGARIS; PSORIATIC ARTHRITIS; QUALITY OF LIFE; RETROSPECTIVE STUDY; SUBCUTANEOUS IMMUNOTHERAPY; TOPICAL TREATMENT; URINARY TRACT INFECTION; VERY ELDERLY; ARTHRITIS; CHEMICALLY INDUCED; CLINICAL TRIAL; COMPLICATION; HEPATITIS B; PSORIASIS; TREATMENT OUTCOME; TUBERCULOSIS;

AGED; AGED, 80 AND OVER; ARTHRITIS; DERMATOLOGIC AGENTS; FEMALE; HEPATITIS B; HUMANS; MALE; PSORIASIS; TREATMENT OUTCOME; TUBERCULOSIS; USTEKINUMAB;

EID: 84913553366     PISSN: 03852407     EISSN: 13468138     Source Type: Journal    
DOI: 10.1111/1346-8138.12653     Document Type: Article

References (29)

1. Grozdev IS, Van Voorhees AS, Gottlieb AB et al. Psoriasis in the elderly: from the Medical Board of the National Psoriasis Foundation. J Am Acad Dermatol 2011; 65: 537-545.
2. Bell LM, Sedlack R, Beard CM, Perry HO, Michet CJ, Kurland LT. Incidence of psoriasis in Rochester, Minn, 1980-1983. Arch Dermatol 1991; 127: 1184-1187.
3. Umezawa Yoshinori NH. Psoriasis. Geriatr Med 2012; 50: 831-835.
4. Coskey RJ. Adverse effects of corticosteroids: I. Topical and intralesional. Clin Dermatol 1986; 4: 155-160.
5. Falck P, Asberg A, Byberg KT et al. Reduced elimination of cyclosporine A in elderly (>65 years) kidney transplant recipients. Transplantation 2008; 86: 1379-1383.
6. Lebwohl M, Ellis C, Gottlieb A et al. Cyclosporine consensus conference: with emphasis on the treatment of psoriasis. J Am Acad Dermatol 1998; 39: 464-475.
7. Ranganath VK, Furst DE. Disease-modifying antirheumatic drug use in the elderly rheumatoid arthritis patient. Rheum Dis Clin North Am 2007; 33: 197-217.
8. Bissonnette R, Ho V, Langley RG. Safety of conventional systemic agents and biologic agents in the treatment of psoriasis. J Cutan Med Surg 2009; 13(Suppl 2): S67-S76.
9. Tsai TF, Ho V, Song M et al. The safety of ustekinumab treatment in patients with moderate-to-severe psoriasis and latent tuberculosis infection. Br J Dermatol 2012; 167: 1145-1152.
10. Tsai TF. Response to: Hepatitis B virus reactivation after ustekinumab treatment. Br J Dermatol 2014; 170: 478-479.
11. Sanchez-Moya AI, Dauden E. Incidence of tuberculosis infection in psoriatic patients on anti-TNF therapy: report of a case series with 144 patients. J Eur Acad Dermatol Venereol 2011; 25: 730-733.
12. Carmona L, Gomez-Reino JJ, Rodriguez-Valverde V et al. Effectiveness of recommendations to prevent reactivation of latent tuberculosis infection in patients treated with tumor necrosis factor antagonists. Arthritis Rheum 2005; 52: 1766-1772.
13. Gomez-Reino JJ, Carmona L, Angel Descalzo M, Biobadaser Group. Risk of tuberculosis in patients treated with tumor necrosis factor antagonists due to incomplete prevention of reactivation of latent infection. Arthritis Rheum 2007; 57: 756-761.
14. O'Quinn DB, Palmer MT, Lee YK, Weaver CT. Emergence of the Th17 pathway and its role in host defense. Adv Immunol 2008; 99: 115-163.
15. Perlmutter A, Mittal A, Menter A. Tuberculosis and tumour necrosis factor-alpha inhibitor therapy: a report of three cases in patients with psoriasis. Comprehensive screening and therapeutic guidelines for clinicians. Br J Dermatol 2009; 160: 8-15.
16. Germann T, Rude E. Interleukin-12. Int Arch Allergy Immunol 1995; 108: 103-112.
17. Flynn JL, Chan J. Immunology of tuberculosis. Annu Rev Immunol 2001; 19: 93-129.
18. Doherty SD, Van Voorhees A, Lebwohl MG, Korman NJ, Young MS, Hsu S, National Psoriasis Foundation. National Psoriasis Foundation consensus statement on screening for latent tuberculosis infection in patients with psoriasis treated with systemic and biologic agents. J Am Acad Dermatol 2008; 59: 209-217.
19. Reich K, Burden AD, Eaton JN, Hawkins NS. Efficacy of biologics in the treatment of moderate to severe psoriasis: a network metaanalysis of randomized controlled trials. Br J Dermatol 2012; 166: 179-188.
20. Igarashi A, Kato T, Kato M, Song M, Nakagawa H, Japanese Ustekinumab Study Group. Efficacy and safety of ustekinumab in Japanese patients with moderate-to-severe plaque-type psoriasis: long-term results from a phase 2/3 clinical trial. J Dermatol 2012; 39: 242-252.
21. Ruiz Salas V, Puig L, Alomar A. Ustekinumab in clinical practice: response depends on dose and previous treatment. J Eur Acad Dermatol Venereol 2012; 26: 508-513.
22. Clemmensen A, Spon M, Skov L, Zachariae C, Gniadecki R. Responses to ustekinumab in the anti-TNF agent-naive vs. anti-TNF agent-exposed patients with psoriasis vulgaris. J Eur Acad Dermatol Venereol 2011; 25: 1037-1040.
23. Ohtsuki M, Nakagawa H, Sugai J et al. Long-term continuous versus intermittent cyclosporin: therapy for psoriasis. J Dermatol 2003; 30: 290-298.
24. Giannetti A, Coppini M, Bertazzoni MG et al. Clinical trial of the efficacy and safety of oral etretinate with calcipotriol cream compared with etretinate alone in moderate-severe psoriasis. J Eur Acad Dermatol Venereol 1999; 13: 91-95.
25. Esposito M, Giunta A, Mazzotta A et al. Efficacy and safety of subcutaneous anti-tumor necrosis factor-alpha agents, etanercept and adalimumab, in elderly patients affected by psoriasis and psoriatic arthritis: an observational long-term study. Dermatology 2012; 225: 312-319.
26. Torii H, Nakagawa H, Japanese Infliximab Study Investigators. Infliximab monotherapy in Japanese patients with moderate-to-severe plaque psoriasis and psoriatic arthritis. A randomized, double-blind, placebo-controlled multicenter trial. J Dermatol Sci 2010; 59: 40-49.
27. Asahina A, Nakagawa H, Etoh T, Ohtsuki M, Adalimumab MSG. Adalimumab in Japanese patients with moderate to severe chronic plaque psoriasis: efficacy and safety results from a Phase II/III randomized controlled study. J Dermatol 2010; 37: 299-310.
28. Harris J, Keane J. How tumour necrosis factor blockers interfere with tuberculosis immunity. Clin Exp Immunol 2010; 161: 1-9.
29. Stamell EF, Kutner A, Viola K, Cohen SR. Ustekinumab associated with flares of psoriatic arthritis. JAMA Dermatol 2013; 149: 1410-1413.